Osmol Therapeutics Secures EU Patent Allowance For Novel Drug Targeting Chemo-Induced Neuropathy

Osmol Therapeutics, a privately held clinical-stage biopharmaceutical company developing treatments to prevent the side effects of chemotherapy, has announced that the European Patent Office (EPO) has allowed its European Union (EU) patent for OSM-0205, the company’s lead drug candidate. The patent, exclusively licensed from Yale University, supports the development and commercialization of OSM-0205 for the prevention of chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI).

Bob Linke, MBA, President and CEO of Osmol Therapeutics, said in a statement, “This allowance builds on the strong foundation for the development and commercialization established for OSM-0205 with the potential to address some of the most challenging and debilitating effects of chemotherapy that impact cancer patients worldwide.”

Barbara Ehrlich, PhD, Professor of Pharmacology at Yale University and Osmol’s Scientific Founder, stated, “Patients undergoing chemotherapy deserve therapies that not only fight cancer but also protect them from the toxicities that impact daily life. Securing this patent represents a significant milestone that validates our science and strengthens our ability to deliver meaningful innovation to cancer patients.”

OSM-0205 is designed to address two of the most common and debilitating side effects experienced by cancer patients undergoing chemotherapy. The patent covers the use of any form of lithium, including intravenous, oral, or other delivery methods for the treatment of CIPN and CICI. This patent has already been granted in the United States and China, and with the EU allowance, Osmol now holds broad international protection for its therapeutic approach. Osmol is currently in the process of completing a financing round that will enable the initiation of a Phase 1 clinical trial to evaluate OSM-0205 in humans. Following the successful completion of this study, the company plans to begin Phase 2 trials in the second half of 2026.

In addition to the newly allowed EU patent, Osmol has filed a provisional patent to expand the potential application of OSM-0205 beyond taxane-based chemotherapies. This includes targeting nerve and cognitive side effects caused by a newer class of cancer treatments known as antibody drug conjugates (ADCs), especially those with microtubule-disrupting agents such as monomethyl auristatin E (MMAE). These ADCs are increasingly associated with severe neuropathy, which can limit both the dosage and duration of treatment. The expanded patent aims to support broader use of OSM-0205 across evolving cancer treatment regimens.